lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
This iconography also makes a striking parallel between hunting and combat, which are treated on an identical footing. The tombs would have been made during the lifetime of the dynast, and illustrated his deeds during his life. Given the date and circumstance of this sarcophagus, the dynast who is illustrated in the hunting and fighting scene may have been related to the Satrap of Hellespontine Phrygia, Pharnabazus, who fought again the Greeks on several occasions, particularly against Agesilaos when the latter attacked and ravaged the area around Daskyleion in 395 BCE. The bones found in the tomb belonged to a male of considerable strength, between 170 and 175 centimetres (67 and 69 in) in height, who died between 25 and 28 years old. He suffered a fall from a considerable height, probably from his horse during combat, many of his limbs having been crushed. He lived for several more years as a cripple, his limbs remaining misaligned, before dying. The sarcophagus could formerly be seen in the Çanakkale Archaeological Museum, where an earlier, 6th century BCE sarcophagus, the Polyxena sarcophagus, was also on display. Both are now located in the Troy Museum.
== Poisoning == The prognosis is good for paracetamol overdoses if treatment is initiated up to 8 hours after the drug has been taken. Most hospitals stock the antidote (acetylcysteine), which replenishes the liver's supply of glutathione, allowing the NAPQI to be metabolized safely. Without early administration of the antidote, fulminant liver failure follows, often in combination with kidney failure, and death generally occurs within several days.
==== MeSH E05.318.740 – statistics ==== MeSH E05.318.740.100 – actuarial analysis MeSH E05.318.740.150 – analysis of variance MeSH E05.318.740.150.500 – multivariate analysis MeSH E05.318.740.200 – area under curve MeSH E05.318.740.250 – cluster analysis MeSH E05.318.740.250.675 – small-area analysis MeSH E05.318.740.250.700 – space-time clustering MeSH E05.318.740.275 – confidence intervals MeSH E05.318.740.300 – data interpretation, statistical MeSH E05.318.740.350 – discriminant analysis MeSH E05.318.740.400 – factor analysis, statistical MeSH E05.318.740.475 – matched-pair analysis MeSH E05.318.740.500 – models, statistical MeSH E05.318.740.500.475 – likelihood functions MeSH E05.318.740.500.500 – linear models MeSH E05.318.740.500.525 – logistic models MeSH E05.318.740.500.600 – models, economic MeSH E05.318.740.500.600.500 – models, econometric MeSH E05.318.740.500.625 – nomograms MeSH E05.318.740.500.700 – proportional hazards models MeSH E05.318.740.525 – monte carlo method MeSH E05.318.740.600 – probability MeSH E05.318.740.600.200 – Bayes' theorem MeSH E05.318.740.600.400 – likelihood functions MeSH E05.318.740.600.500 – markov chains MeSH E05.318.740.600.600 – odds ratio MeSH E05.318.740.600.700 – proportional hazards models MeSH E05.318.740.600.800 – risk MeSH E05.318.740.600.800.450 – logistic models MeSH E05.318.740.600.800.715 – risk assessment MeSH E05.318.740.600.800.725 – risk factors MeSH E05.318.740.600.900 – uncertainty MeSH E05.318.740.750 – regression analysis MeSH E05.318.740.750.400 – least-squares analysis MeSH E05.318.740.750.425 – linear models MeSH E05.318.740.750.450 – logistic models MeSH E05.318.740.750.725 – proportional hazards models MeSH E05.318.740.872 – sensitivity and specificity MeSH E05.318.740.994 – statistical distributions MeSH E05.318.740.994.250 – binomial distribution MeSH E05.318.740.994.300 – chi-square distribution MeSH E05.318.740.994.500 – normal distribution MeSH E05.318.740.994.750 – poisson distribution MeSH E05.318.740.995 – statistics, nonparametric MeSH E05.318.740.996 – stochastic processes MeSH E05.318.740.996.500 – markov chains MeSH E05.318.740.998 – survival analysis MeSH E05.318.740.998.300 – disease-free survival
=== Stored-waveform inverse Fourier transform === Stored-waveform inverse Fourier transform (SWIFT) is a method for the creation of excitation waveforms for FTMS. The time-domain excitation waveform is formed from the inverse Fourier transform of the appropriate frequency-domain excitation spectrum, which is chosen to excite the resonance frequencies of selected ions. The SWIFT procedure can be used to select ions for tandem mass spectrometry experiments.
Sources: en.wikipedia.org
=== Antivenene research and production === In 1928, CSL also became involved in antivenene (antivenom) manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute. This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930 and its commercial release in 1931. In 1934, the research on snake venoms was transferred from the Hall Institute to CSL under the direction of former snake showman and herpetologist Tom "Pambo" Eades. This represented the initiation of research at the laboratories – an outcome its directors had been seeking for over a decade. The relationship with the Hall Institute continued until World War II, particularly via joint projects on viral diseases including polio and influenza coordinated by Frank Macfarlane Burnet and Esmond "Bill" Keogh. Keogh played an important role in the establishment of penicillin production at CSL in 1944 – a critical wartime achievement.
=== Early academic research === In academic discourse, the initial mention of ayahuasca dates back to Manuel Villavicencio's 1858 book, "Geografía de la República del Ecuador." This work vividly delineates the employment and rituals involving ayahuasca by the Jivaro people. Concurrently, Richard Spruce embarked on an Amazonian expedition in 1852 to collect and classify previously unidentified botanical specimens. During this journey, Spruce encountered and documented Banisteriopsis caapi (at time named Banisteria caapi) and observed an ayahuasca ceremony among the Tucano community situated along the Vaupés River. Subsequently, Spruce uncovered the usage and cultivation of B. caapi among various indigenous groups dispersed across the Amazon and Orinoco basins, like the Guahibo and Sápara. These multifarious encounters, together with Spruce's personal accounts of subjective ayahuasca experiences, were collated in his work, "Notes of a Botanist On The Amazon and Andes.". By the end of the century, other explorers and anthropologists contributed more extensive documentation concerning ayahuasca, notably the Theodor Koch-Grünberg's documents about Tucano and Arecuna's rituals and ceremonies, Stradelli's first-hand reports of ayahuasca rituals and mythology along the Jurupari and Vaupés and Alfred Simson's first description of admixture of several ingredients in the making of ayahuasca in Putumayo region, published in 1886.
=== Selected publications === Ariely, Dan; Loewenstein, George; Prelec, Drazen (2003), "Coherent Arbitrariness: Stable demand curves without stable preferences", The Quarterly Journal of Economics, 118 (1): 73–106, doi:10.1162/00335530360535153, archived from the original on April 4, 2012 Ariely, Dan (2000), "Controlling information flow: Effects on consumers' decision making and preference", Journal of Consumer Research, 27 (2): 233–248, CiteSeerX 10.1.1.203.1798, doi:10.1086/314322 {{citation}}: Cite uses deprecated parameter |citeseerx= (help) Ariely, Dan; Wertenbroch, Klaus (2002), "Procrastination, Deadlines, and Performance: Self-Control by Precommitment" (PDF), Psychological Science, 13 (3): 219–224, doi:10.1111/1467-9280.00441, PMID 12009041, S2CID 3025329 Heyman, James; Ariely, Dan (2004), "Effort for Payment: A Tale of Two markets" (PDF), Psychological Science, 15 (11): 787–793(7), doi:10.1111/j.0956-7976.2004.00757.x, PMID 15482452, S2CID 8573184 Carmon, Ziv; Ariely, Dan (2000), "Focusing on the Forgone: Why Value can Appear so Different to Buyers and Sellers" (PDF), Journal of Consumer Research, 27 (3): 360–370, doi:10.1086/317590 Shiv, Baba; Carmon, Ziv; Ariely, Dan (2005), "Placebo Effects of Marketing Actions: Consumers May Get What They Pay For" (PDF), Journal of Marketing Research, XXII (4): 383–393, doi:10.1509/jmkr.2005.42.4.383, S2CID 14170707 Mazar, Nina; Ariely, Dan (2006), "Dishonesty in Everyday Life and Its Policy Implications" (PDF), Journal of Public Policy & Marketing, 25 (1): 117–126, doi:10.1509/jppm.25.1.117, S2CID 2813683 Lee, Leonard; Frederick, Shane; Ariely, Dan (2006), "Try it, you'll like it: The influence of expectation, consumption, and revelation on preferences for beer" (PDF), Psychological Science, 17 (12): 1054–1058, doi:10.1111/j.1467-9280.2006.01829.x, PMID 17201787, S2CID 1252769 Ariely, Dan; Gregory S. Berns (March 3, 2010). "Neuromarketing: the hope and hype of neuroimaging in business" (PDF). Nature Reviews Neuroscience. 11 (4): 284–292. doi:10.1038/nrn2795. PMC 2875927. PMID 20197790. Archived from the original (PDF) on July 11, 2013. Ariely, Dan; Michael I. Norton; Daniel Mochon (July 2012). "The IKEA effect: When labor leads to love" (PDF). Journal of Consumer Psychology. 3. 22 (3): 453–460. doi:10.1016/j.jcps.2011.08.002. Archived from the original (PDF) on May 20, 2014.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.